CLIN CANCER RES:c-Fos可以增强头颈部鳞状细胞癌肿瘤干细胞样细胞特性

2017-07-04 MedSci MedSci原创

头颈部鳞状细胞癌(HNSCC)是世界范围内排名第6位的肿瘤。尽管手术技巧、放化疗以及支持治疗等治疗方式的提高改善了HNSCC患者的生活质量,但是局部及远处复发仍然很常见。近期研究表明肿瘤干细胞样细胞(CSC)在复发及化疗抵抗中起到了重要的作用。在HNSCC细胞中c-Fos显着上调,而c-Fos上调对HNSCC-CSC的影响尚不清楚。CLIN CANCER RES近期发表了一篇文章,研究c-Fos在

头颈部鳞状细胞癌(HNSCC)是世界范围内排名第6位的肿瘤。尽管手术技巧、放化疗以及支持治疗等治疗方式的提高改善了HNSCC患者的生活质量,但是局部及远处复发仍然很常见。近期研究表明肿瘤干细胞样细胞(CSC)在复发及化疗抵抗中起到了重要的作用。在HNSCC细胞中c-Fos显着上调,而c-Fos上调对HNSCC-CSC的影响尚不清楚。CLIN CANCER RES近期发表了一篇文章,研究c-Fos在HNSCC干细胞更新及肿瘤生长中的作用。

作者构建了异常表达c-Fos基因的稳定HNSCC细胞系。在裸鼠中,正常细胞MDA1386Tu外源性表达c-Fos可以使细胞具有致瘤性。在免疫功能低下的老鼠中皮下种植c-Fos过表达的Cal27细胞系后,与亲代细胞相比肿瘤增殖增强。进一步的机制研究表明c-Fos过表达可以增强上皮间质转化(EMT)以及CSC标记物表达(Nanog、c-Myc、Sox2以及Notch1)。在HNSCC细胞中c-Fos过表达会增强pERK及cyclinD1表达。

文章最后认为,HNSCC细胞中c-Fos在EMT及肿瘤干细胞重编程中起到了重要作用,针对CSC改善HNSCC治疗方式具有一定前景。

原始出处:
Naoshad Muhammad,Sourav Bhattacharya,et al.Involvement of c-Fos in the Promotion of Cancer Stem-like Cell Properties in Head and Neck Squanmous Cell Carcinoma.CLIN CANCER RES.June 2017 doi:10.1158/1078-0432.CCR-16-2811

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1978519, encodeId=09a019e8519aa, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Nov 28 01:49:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297681, encodeId=9aa9129e681c5, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Jul 06 10:49:00 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491787, encodeId=f6a41491e8774, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Thu Jul 06 10:49:00 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589721, encodeId=8e541589e2177, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Thu Jul 06 10:49:00 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218672, encodeId=8f7c2186e2f5, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Jul 05 06:26:07 CST 2017, time=2017-07-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1978519, encodeId=09a019e8519aa, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Nov 28 01:49:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297681, encodeId=9aa9129e681c5, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Jul 06 10:49:00 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491787, encodeId=f6a41491e8774, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Thu Jul 06 10:49:00 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589721, encodeId=8e541589e2177, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Thu Jul 06 10:49:00 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218672, encodeId=8f7c2186e2f5, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Jul 05 06:26:07 CST 2017, time=2017-07-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1978519, encodeId=09a019e8519aa, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Nov 28 01:49:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297681, encodeId=9aa9129e681c5, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Jul 06 10:49:00 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491787, encodeId=f6a41491e8774, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Thu Jul 06 10:49:00 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589721, encodeId=8e541589e2177, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Thu Jul 06 10:49:00 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218672, encodeId=8f7c2186e2f5, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Jul 05 06:26:07 CST 2017, time=2017-07-05, status=1, ipAttribution=)]
    2017-07-06 wshxjq
  4. [GetPortalCommentsPageByObjectIdResponse(id=1978519, encodeId=09a019e8519aa, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Nov 28 01:49:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297681, encodeId=9aa9129e681c5, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Jul 06 10:49:00 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491787, encodeId=f6a41491e8774, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Thu Jul 06 10:49:00 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589721, encodeId=8e541589e2177, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Thu Jul 06 10:49:00 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218672, encodeId=8f7c2186e2f5, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Jul 05 06:26:07 CST 2017, time=2017-07-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1978519, encodeId=09a019e8519aa, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Nov 28 01:49:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297681, encodeId=9aa9129e681c5, content=<a href='/topic/show?id=f999444352f' target=_blank style='color:#2F92EE;'>#头颈部鳞状细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44435, encryptionId=f999444352f, topicName=头颈部鳞状细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Thu Jul 06 10:49:00 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491787, encodeId=f6a41491e8774, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Thu Jul 06 10:49:00 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589721, encodeId=8e541589e2177, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Thu Jul 06 10:49:00 CST 2017, time=2017-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218672, encodeId=8f7c2186e2f5, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Wed Jul 05 06:26:07 CST 2017, time=2017-07-05, status=1, ipAttribution=)]
    2017-07-05 大爰

    学习了谢谢分享!!

    0

相关资讯

百时美Opdivo获欧盟CHMP推荐批准,将成欧洲治疗头颈部鳞状细胞癌(SCCHN)的肿瘤免疫疗法

美国制药巨头百时美施贵宝(BMS)肿瘤免疫管线近日在欧盟监管方面传来喜讯。欧洲药品管理局(EMA)人用医药产品委员会(CHMP)发布积极意见,推荐批准PD-1免疫疗法Opdivo作为一种单药疗法,用于含铂化疗方案治疗期间或治疗后病情进展的头颈部鳞状细胞癌(SCCHN)成人患者的治疗。Opdivo也是首个获得欧盟CHMP推荐用于铂

CLIN CANCER RES:Motolimod联合西妥昔单抗治疗复发或转移性头颈部鳞状细胞癌

Toll样受体(TLR)是免疫反应的关键调节因子,TLR激动剂对于增强头颈部鳞状细胞癌(SCCHN)治疗效果很重要。Motolimod(VTX-2337)是一种选择性的TLR8激动剂,激活NK细胞、DC细胞以及单核细胞。CLIN CANCER RES近期发表了一篇文章,报道Motolimod联合西妥昔单抗治疗头颈部鳞状细胞癌患者的临床试验结果。

2016头颈部鳞状细胞癌颈淋巴结转移处理的专家共识发布

目前,头颈部鳞状细胞癌(简称头颈鳞癌)占头颈恶性肿瘤的90%以上,已成为全球第六大恶性肿瘤,每年新发65万例、死亡35万例。而颈淋巴结转移是头颈各部位肿瘤发生转移的最常见方式,约有50%头颈鳞癌患者在确诊时已经存在隐匿性或明显的颈淋巴结受累。颈淋巴结转移是影响头颈鳞癌治疗效果的重要和独立预后因素,与不伴颈淋巴结转移的患者相比,发生颈淋巴结转移的头颈鳞癌患者的5年生存率几乎下降一半。因此,正确掌握颈

2016 CCO指南:头颈部鳞状细胞癌的系统治疗

2016年8月,加拿大安大略癌症治疗中心(CCO)发布了头颈部鳞状细胞癌的系统治疗指南,该指南的目的是基于关于局部晚期头颈部非转移性鳞状细胞癌治疗策略的RCT试验数据,提供推荐建议。

JAMA Oncology:头颈部鳞状细胞癌KRAS变异与西妥昔单抗反应

在局部晚期头颈部鳞状细胞癌(HNSCC)中,找到放疗及西妥昔单抗治疗反应的标志物很重要。JAMA Oncology近期发表了一篇文章,研究KRAS变异作为西妥昔单抗反应反应、放疗及顺铂化疗的免疫改变的预测标志物,评估KRAS变异与p16状态以及TGF-β1的关系。

Cancer:口腔卫生会影响HPV相关头颈部鳞状细胞癌的患病风险吗?

背景:口腔卫生指标差(包括吸烟),已被证明可以增加的头颈部鳞状细胞癌,特别是口咽部鳞状细胞癌(OPSCC)的风险。但很少有研究探讨该联系是否也与人类乳头瘤病毒(HPV)状态有关。